Remove Biomarkers Remove Stroke Remove Thrombolysis
article thumbnail

Abstract 106: Circulating Interleukin-6 Levels Early During Active Stroke Estimate Time of Stroke Onset: Potential New Clinical Biomarker Tool From a Mobile Stroke Unit

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page A106-A106, February 1, 2024. Background:Circulating interleukin-6 (IL-6) concentrations are elevated in acute stroke but the timing of the IL-6 response in humans is unknown. We used a mobile stroke unit (MSU) to identify IL-6 levels within minutes of symptom onset. pg/mL, respectively.

Stroke 40
article thumbnail

Abstract WMP8: Tenecteplase vs Alteplase: is Pro-Inflammatory and Procoagulant Response Any Different in Acute Ischemic Stroke?

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page AWMP8-AWMP8, February 1, 2024. Introduction:Thrombolysis in acute ischemic stroke (AIS) using Tenecteplase (TNK) is gaining popularity compared to Alteplase (ALT) for its practical advantages. The baseline demographics, vascular risk factors, and admission stroke severity were similar.

Stroke 40
article thumbnail

Abstract 54: Investigating the Relationship Between Reperfusion and Cerebral Edema Using Novel Cerebrospinal Fluid and Net Water Uptake Biomarkers

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page A54-A54, February 1, 2024. Introduction:Studies show that successful reperfusion after large-vessel occlusion (LVO) stroke can lead to reduced mass effect and midline shift (MLS).

article thumbnail

Abstract TP146: Collateral Status-Based Model for Hemorrhagic Transformation in Successfully Recanalized Medium Vessel Occlusions

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page ATP146-ATP146, February 1, 2024. Introduction:Collateral status imaging parameters are associated with predicting hemorrhagic transformation (HT) in acute ischemic stroke caused by large vessel occlusions. p=0.006); CBV index (aOR 0.0002, 95% CI 0-0.1,

article thumbnail

Abstract 28: Patients Randomised to Glenzocimab Suffered Less Haemorrhagic Transformation at 24 Hours Compared to Placebo: AI-Imaging Sub-Analysis of the ACTIMIS Trial

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page A28-A28, February 1, 2024. Introduction:ACTIMIS (NCT03803007) was a randomized phase 1b/2a clinical trial evaluating glenzocimab, a monoclonal antibody fragment targeting platelet receptor glycoprotein VI in patients with acute ischemic stroke treated by thrombolysis.

article thumbnail

Abstract TP127: Pretreatment CT Collateral Parameters Predict Good Outcomes in Successfully Recanalized Middle Cerebral Artery Distal Medium Vessel Occlusions

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page ATP127-ATP127, February 1, 2024. Background/Purpose:Distal medium vessel occlusions (DMVOs) account for a large percentage of vessel occlusions resulting in acute ischemic stroke (AIS) with disabling symptoms. years old [mean+-SD], 35 female). for optimal sensitivity (71% [52.0-85.8%])

article thumbnail

Abstract WMP64: Late Lesion Growth Following Endovascular Therapy: Is 24 Hours Too Early to Assess Acute Infarct Size Including the Effects of Secondary Injury?

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page AWMP64-AWMP64, February 1, 2024. Additionally it can serve as an imaging biomarker for the development of adjunctive therapies to mitigate reperfusion injury. Successful recanalization was achieved in 86% and 67% had complete reperfusion, with an overall favorable clinical outcome rate of 54%.